FOLFOXIRI-Bev as first-line treatment in patients with metastatic colorectal cancer: a systematic review of RCT

被引：0
|
作者：
Luih, B. Stephanie [1 ]
Samudra, E. [1 ]
Suwongto, G. Sonia [1 ]
Glory, H. [1 ]
Colfoort, K. [1 ]
Wirajaya, P. [1 ]
Kurniawan, A. [1 ]
机构：
[1] Pelita Harapan Univ, Sch Med Pelita Harapan, Banten, Indonesia
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.588
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO42-1
引用
收藏
页码：S1349 / S1350
页数：2
相关论文
共 50 条
  • [31] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    M J Safont
    A Salud
    F Losa
    C García-Girón
    C Bosch
    P Escudero
    R López
    C Madroñal
    M Bolaños
    M Gil
    A Llombart
    J Castro-Carpeño
    M González-Barón
    British Journal of Cancer, 2010, 102 : 1468 - 1473
  • [32] Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer
    Karacetin, D.
    Yalcin, B.
    Okten, B.
    Ozturk, S.
    Maral, O.
    Incekara, O.
    JOURNAL OF BUON, 2009, 14 (04): : 605 - 608
  • [33] Bevacizumab in combination with chemotherapy: First-line treatment of patients with metastatic colorectal cancer
    Hochster, Howard S.
    SEMINARS IN ONCOLOGY, 2006, 33 (05) : S8 - S14
  • [34] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    Feliu, J.
    Safont, M. J.
    Salud, A.
    Losa, F.
    Garcia-Giron, C.
    Bosch, C.
    Escudero, P.
    Lopez, R.
    Madronal, C.
    Bolanos, M.
    Gil, M.
    Llombart, A.
    Castro-Carpeno, J.
    Gonzalez-Baron, M.
    BRITISH JOURNAL OF CANCER, 2010, 102 (10) : 1468 - 1473
  • [35] Doublet (FOLFOX or FOLFIRI) versus triplet (FOLFOXIRI) backbone chemotherapy regimen as first-line treatment of metastatic colorectal cancer: A meta-analysis and systematic review.
    Jindal, Vishal
    Gupta, Ruby
    Sahu, Kamal Kant
    Rahi, Mandeep Singh
    Stender, Michael J.
    Jaiyesimi, Ishmael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
    Masi, Gianluca
    Loupakis, Fotios
    Salvatore, Lisa
    Fornaro, Lorenzo
    Cremolini, Chiara
    Cupini, Samanta
    Ciarlo, Andrea
    Del Monte, Francesca
    Cortesi, Enrico
    Amoroso, Domenico
    Granetto, Cristina
    Fontanini, Gabriella
    Sensi, Elisa
    Lupi, Cristiana
    Andreuccetti, Michele
    Falcone, Alfredo
    LANCET ONCOLOGY, 2010, 11 (09): : 845 - 852
  • [37] FOLFOXIRI versus FOLFOX/FOLFIRI plus Bevacizumab as first-line treatment in metastatic colorectal cancer: A systematic review and network Meta-analysis of phase III study
    Zhang, J.
    Deng, Y.
    Cai, Y.
    Hu, H.
    Xiao, J.
    Ling, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S362 - S363
  • [38] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.
    Cremolini, Chiara
    Loupakis, Fotios
    Masi, Gianluca
    Zagonel, Vittorina
    Bergamo, Francesca
    Salvatore, Lisa
    Cortesi, Enrico
    Tomasello, Gianluca
    Ronzoni, Monica
    Pinta, Francesco
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Amoroso, Domenico
    Sonaglio, Claudia
    De Stefano, Alfonso
    Boni, Corrado
    Allegrini, Giacomo
    Boni, Luca
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [39] Safety analysis of phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer
    Taniguchi, H.
    Kito, Y.
    Satake, H.
    Horie, Y.
    Yamada, T.
    Esaki, T.
    Denda, T.
    Mori, K.
    Yamazaki, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Monoclonal Antibodies for First-Line Treatment of Metastatic Colorectal Cancer
    Liao, Pei-Fei
    Wu, Ta-Wei
    Peng, Tzu-Rong
    AMERICAN JOURNAL OF THERAPEUTICS, 2024, 31 (03) : e286 - e297
12345